Loading...
Loading...
dealREPORTER is reporting that Genzyme
GENZ is moving higher as unconfirmed sources are saying that a deal for the company can happen within the next couple of weeks.
Genzyme has been the target of Sanofi-Aventis
SNY, which bid for the company, but was rebuffed by shareholders.
At last check, shares were down 20 cents to $71.50, but had been down much more than that earlier.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in